46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00831649 (ClinicalTrials.gov)	September 2004	27/1/2009	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201	Rheumatoid Arthritis	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Terminated	18 Years	75 Years	Both		Phase 2	NULL
2	NCT00083759 (ClinicalTrials.gov)	May 2004	1/6/2004	Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate	A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)	Rheumatoid Arthritis	Drug: natalizumab;Drug: placebo	Biogen	Elan Pharmaceuticals	Terminated	18 Years	75 Years	All	299	Phase 2	United States;Canada